Inhibition of capsaicin-driven nasal hyper-reactivity by SB-705498, a TRPV1 antagonist

British Journal of Clinical Pharmacology

Volumn 77, Issue 5, 2014, Pages 777-788

  Holland, Carlijn ^a   Van Drunen, Cornelis ^a   Denyer, Jane ^b   Smart, Kevin ^b   Segboer, Christine ^a   Terreehorst, Ingrid ^a   Newlands, Amy ^b   Beerahee, Misba ^b   Fokkens, Wytske ^a   Tsitoura, Daphne C ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

capsaicin challenge; intranasal SB 705498; nasal hyper responsiveness; rhinitis; TRPV1

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; CAPSAICIN; PLACEBO; PYRROLIDINE DERIVATIVE; TRPV1 RECEPTOR; UREA; VANILLOID RECEPTOR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NOSE OBSTRUCTION; OROPHARYNX PAIN; PERENNIAL RHINITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; REPEATED DRUG DOSE; RHINORRHEA; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VASOMOTOR RHINITIS; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; MIDDLE AGED; RHINITIS; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; CAPSAICIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRROLIDINES; RHINITIS; TRPV CATION CHANNELS; UREA; VISUAL ANALOG SCALE;

EID: 84899107723     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12219     Document Type: Article

References (42)

1. Varjonen E, Kalimo K, Lammintausta K, Terho P,. Prevalence of atopic disorders among adolescents in Turku, Finland. Allergy 1992; 47: 243-248.
2. Druce H,. Allergic and nonallergic rhinitis. In: Allergy Principles and Practice, 5th edn, eds, Middleton E, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger W, Busse WW,. St Louis, MO: Mosby-Year Book, 1998; 1005-1016.
3. Settipane RA,. Rhinitis: a dose of epidemiological reality. Allergy Asthma Proc 2003; 24: 147-154.
4. Sarin S, Undem B, Sanico A, Togias A,. The role of the nervous system in rhinitis. J Allerg Clin Immunol 2006; 118: 999-1014.
5. Alenmyr L, Greiff L, Andersson M, Sterner O, Zygmunt PM, Högestätt ED,. Effect of mucosal TRPV1 inhibition in allergic rhinitis. Basic Clin Pharmacol Toxicol 2012; 110: 264-268.
6. Van Rijswijk JB, Blom HM, Fokkens WJ,. Idiopathic rhinitis, the ongoing quest. Allergy 2005; 60: 1471-1481.
7. Van Rijswijk JB, Boeke EL, Keizer JM, Mulder PG, Blom H, Fokkens WJ,. Intranasal capsaicin reduces nasal hyperreactivity in idiopathic rhinitis: a double-blind randomized application regimen study. Allergy 2003; 58: 754-761.
8. Alexander SPH, Mathie A, Peters JA,. Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 2011; 164 (Suppl. 1): S1-S324.
9. Caterina MJ, Julius D,. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001; 24: 487-517.
10. Gunthorpe MJ, Benham CD, Randall A, Davis JB,. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci 2002; 23: 183-191.
11. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh Y-G, Kim D, Oh U,. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000; 97: 6155-6160.
12. Seki N, Shirasaki H, Kikuchi M, Sakamoto T, Watanabe N, Himi T,. Expression and localization of TRPV1 in human nasal mucosa. Rhinology 2006; 44: 128-134.
13. O'Hanlon S, Facer P, Simpson KD, Sandhu G, Saleh HA, Anand P,. Neuronal markers in allergic rhinitis: expression and correlation with sensory testing. Laryngoscope 2007; 117: 1519-1527.
14. Geppetti P, Materazzi S, Nicoletti P,. The transient receptor potential vanilloid 1: role in airway inflammation and disease. Eur J Pharmacol 2006; 533: 207-214.
15. Lee LY, Gu Q,. Role of TRPV1 in inflammation-induced airway hypersensitivity. Cur Opin Pharmacol 2009; 9: 243-249.
16. Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ, Smart D, Sargent B, Sanderson D, Randall AD, Gunthorpe MJ, Davis JB,. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006; 16: 3287-3291.
17. Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD, Brough S, Wright J, Egerton J, Lappin SC, Holland VA, Winborn K, Thompson M, Rami HK, Randall A, Davis JB,. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and hear-mediated activation of the receptor. J Pharmacol Exp Ther 2007; 321: 1183-1192.
18. Gunthorpe MJ, Chizh BA,. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today 2009; 14: 56-67.
19. Changani K, Hotee S, Campbell S, Pindoria K, Dinnewell L, Saklatvala P, Thompson S-A, Coe D, Biggadike K, Vitulli G, Lines M, Busza A, Denyer J,. Efficacy of the TRPV1 antagonist SB-705498 in an MRI guinea pig model of rhinitis. ERS Annual Congress, Amsterdam, 2011.
20. World Medical Association. Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Available at http://www.wma.net/en/ 30publications/10policies/b3/ (last accessed 31 October 2011).
21. Tarhan E,. Acoustic rhinometry in humans: accuracy of nasal passage area estimates, and ability to quantify paranasal sinus volume and ostium size. J Appl Physiol 2005; 99: 616-623.
22. Chizh BA, O'Donnell MB, Napolitano A, Wang J, Brooke AC, Aylott MC, Bullman JN, Gray EJ, Lai RY, Williams PM, Appleby JM,. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007; 132: 132-141.
23. Lambert GA, Davis JB, Appleby JM, Chizh BA, Hoskin KL, Zagami AS,. The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 2009; 380: 311-325.
24. Finney DJ,. A computer program for parallel line bioassays. J Pharmacol Exp Ther 1976; 198: 497-506.
25. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D,. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-824.
26. Gavva NR, Bannon AW, Supraneni S, Hovland DN Jr, Lehto SG, Gore A,. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci 2007; 27: 3366-3374.
27. Wong GY, Gavva NR,. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev 2009; 60: 267-277.
28. Krarup AL, Ny L, Astrand M, Bajor A, Hvid-Jensen F, Hansen MB, Simren M, Funch-jensen P, Drewes AM,. Randomised clinical trial; the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther 2011; 33: 1113-1122.
29. Round P, Priestley A, Robinson J,. An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol 2011; 72: 921-931.
30. Steiner AA, Turek VF, Almeida MC, Burmeister JJ, Oliveira DL, Roberts JL, Bannon AW, Norman MH, Louis JC, Treanor JJ, Gavva NR, Romanovsky AA,. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J Neurosci 2007; 27: 7459-7468.
31. Romanovsky AA, Almeida MC, Garami A, Steiner AA, Norman MH, Morrison SF, Nakamura K, Burmeister JJ, Nucci TB,. The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. Pharmacol Rev 2009; 61: 228-261.
32. Borgstrom L, Nillsson M,. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res 1990; 7: 1068-1070.
33. McDowell JE, Mackie AE, Ventresca GP, Bye A,. Pharmacokinetics and bioavailability of intranasal fluticasone in humans. Clin Drug Invest 1997; 1: 44-52.
34. Squillante E,. Measurement of nasal residence time by microdialysis. Curr Sep 2002; 19: 127-130.
35. Rang HP, Ritter JM,. A new kind of drug antagonism: evidence that agonists cause a molecular change in acetylcholine receptors. Mol Pharmacol 1969; 5: 394-411.
36. Teixeira RU, Zappelini CE, Alves FS, da Costa EA,. Peak nasal inspiratory flow evaluation as an objective method of measuring nasal airflow. Braz J Otorhinolaryngol 2011; 77: 473-480.
37. Sanico AM, Philip G, Proud D, Naclerio RM, Togias A,. Comparison of nasal mucosal responsiveness to neuronal stimulation in non-allergic and allergic rhinitis: effects of capsaicin nasal challenge. Clin Exp Allergy 1998; 28: 92-100.
38. Van Crombruggen K, Van Nassauw L, Derycke L, Timmermans J-P, Holtappels G, Hall D, Bachert C,. Capsaicin-induced vasodilatation in human nasal vasculature is mediated by modulation of cyclooxygenase-2 activity and abrogated by sulprostone. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 613-626.
39. Yeon D, Kwon S, Lee Y, Leem J, Nam T, Ahn D,. Capsaicin-induced relaxation in rabbit coronary artery. J Vet Med Sci 2001; 63: 499-503.
40. Gupta S, Lozano-Cuenca J, Villalõn CM, de Vries R, Garrelds IM, Avezaat CJ, van Kats JP, Saxena PR, MaassenVanDenBrink A,. Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 29-38.
41. Fujimoto S, Mori M,. Characterization of capsaicin-induced, capsazepine-insensitive relaxation of ileal smooth muscle of rats. Eur J Pharmacol 2004; 487: 175-182.
42. Chen CW, Lee ST, Wu WT, Fu WM, Ho FM, Lin WW,. Signal transduction for inhibition of inducible nitric oxide synthase and cyclooxygenase-2 induction by capsaicin and related analogs in macrophages. Br J Pharmacol 2003; 140: 1077-1087.